8-K: BridgeBio Pharma Reports Strong Q4, Advances Key Pipeline

BridgeBio Pharma announced preliminary Q4 and full-year 2025 financial results, significant commercial progress for Attruby, and positive clinical and regulatory updates across its late-stage pipeline.

Summary

• Preliminary unaudited Q4 2025 net Attruby product revenue reached $146.0 million, with full-year 2025 revenue at $362.4 million.
• The company estimates approximately $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Attruby (acoramidis) is rapidly becoming a first-choice therapy for newly diagnosed ATTR-CM patients, with 6,629 unique patient prescriptions from 1,632 prescribers as of December 31, 2025, and an estimated >25% share of new-to-brand prescriptions.
• A new TTR amyloid depleter antibody program was announced for ATTR-CM, aiming for disease reversal and expected to advance into the clinic between 2027-2028.
• The Phase 3 FORTIFY study of BBP-418 for LGMD2I/R9 demonstrated broad benefit across all subgroups and a statistically significant 2.6 point benefit on NSAD relative to placebo at 12 months, leading the FDA to recommend orienting the NDA toward traditional full approval.
• BridgeBio intends to submit an NDA for BBP-418 in the first half of 2026.
• For encaleret, the Phase 3 CALIBRATE trial for ADH1 achieved a 76% responder rate at 24 weeks, and the company plans to submit an NDA in the first half of 2026.
• The RECLAIM-HP Phase 3 trial of encaleret for chronic hypoparathyroidism is expected to initiate in Summer 2026 following a successful End of Phase 2 interaction with the FDA.
• Last Participant Last Visit (LPLV) was achieved for PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia, with topline results expected by the end of Q1 2026.
• Last Patient In (LPI) was achieved for the Phase 2 portion of ACCEL 2/3, the registrational study of infigratinib for children with hypochondroplasia.
• The BBP-812 pivotal trial for Canavan disease is ongoing, with a current path to a potential BLA filing in 2027 based on reductions in urine NAA and motor function improvements.
• GondolaBio's PORT-77 Phase 2a trial for Erythropoietic Protoporphyria (EPP) showed dose-dependent reductions in plasma PPIX (up to ~75%) and a clean safety profile.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical trial results across multiple late-stage pipeline programs, strong commercial performance for Attruby, and a robust financial position. The FDA's recommendations for traditional approval paths for BBP-418 and the advancement of other programs indicate significant de-risking and future growth potential.

Positives

• Strong preliminary unaudited Q4 2025 net Attruby product revenue of $146.0 million and full-year 2025 revenue of $362.4 million.
• Robust cash position with approximately $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing ample funding for pipeline advancement and launches.
• Attruby is gaining significant commercial traction, evidenced by 6,629 unique patient prescriptions and 1,632 prescribers, capturing an estimated >25% share of new-to-brand prescriptions for ATTR-CM.
• Attruby demonstrated significant clinical benefits, including a 42% reduction in composite cardiovascular outcomes and a 50% reduction in cardiovascular-related hospitalizations at Month 30, with separation of curves starting by Month 1.
• Positive interim Phase 3 results for BBP-418 in LGMD2I/R9, showing broad benefit across all subgroups and a highly clinically meaningful and statistically significant 2.6 point benefit on NSAD relative to placebo at 12 months (p=0.0001).
• FDA recommended orienting the BBP-418 NDA toward traditional full approval, indicating strong data.
• Excellent Phase 3 CALIBRATE results for encaleret in ADH1, with a 76% responder rate and 91% of participants achieving iPTH above the lower limit of the reference range, demonstrating superiority to conventional therapy.
• Significant progress in ADH1 diagnosis, with >1,700 unique patients identified since October 2023, supported by new ICD-10 codes and updated treatment guidelines.
• Advancement of encaleret into Phase 3 for chronic hypoparathyroidism (CHP) with FDA alignment, building on positive Phase 2 data showing normalization of blood and urine calcium.
• Key milestones achieved for infigratinib, including LPLV for the Phase 3 achondroplasia trial (topline Q1 2026) and LPI for the Phase 2 hypochondroplasia trial.
• Infigratinib is positioned as a potentially best-in-class treatment for achondroplasia, with strong preclinical efficacy and clinical trial results, and a favorable oral administration.
• BBP-812 for Canavan disease shows promising dose-dependent reductions in urine NAA and motor function improvements, with FDA openness to accelerated approval.
• GondolaBio's PORT-77 for EPP demonstrated significant and rapid plasma PPIX reduction (up to ~75%) and a clean safety profile in Phase 2a, achieving proof-of-concept.
• The company's decentralized model is proving effective in delivering transformative medicines across multiple genetic diseases.

Negatives

• The financial results presented are preliminary and unaudited, subject to change upon completion of year-end audit procedures.
• The new TTR amyloid depleter program is still early-stage, with clinical advancement not expected until 2027-2028.
• The company operates in a very competitive and rapidly changing environment, which poses ongoing challenges.

Risks

• Preliminary and unaudited financial estimates may change.
• Initial and ongoing data from preclinical studies and clinical trials may not be indicative of final data.
• The design and success of ongoing and planned clinical trials are uncertain.
• Future regulatory filings, approvals, and sales are not guaranteed.
• The FDA or other regulatory agencies may not agree with the company's regulatory approval strategies, components of filings, clinical trial designs, conduct, methodologies, or the sufficiency of data submitted.
• The continuing success of collaborations is not assured.
• The company's ability to obtain additional funding in the future.
• Potential volatility in the company's share price.
• Impacts of current macroeconomic and geopolitical events, including hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation, and changing interest rates, on business operations and expectations.
• Operating in a very competitive and rapidly changing environment where new risks emerge.

Future Outlook

The company anticipates significant progress in 2026 and beyond, including the submission of New Drug Applications for BBP-418 and encaleret in the first half of 2026, with expected FDA approvals and launches in the second half of 2026 and first half of 2027, respectively. Topline results for infigratinib in achondroplasia are expected by the end of Q1 2026. A new TTR amyloid depleter program is slated to enter the clinic between 2027-2028, and a potential BLA filing for BBP-812 is targeted for 2027. The company is well-financed to support these milestones and aims to double the number of patients it serves by the end of 2026.

Management Comments

• "BridgeBio was built on the belief that if you start with patients, move with urgency, and stay disciplined on science and data, you can deliver transformative medicines with unprecedented results quickly, safely, and effectively."
• "Over the past decade, we've built a company that proves this model. Today, we're seeing progress widely across that decentralized model, allowing us to drive impact for several different communities and hopefully doubling the number of patients that we're able to serve by the end of 2026."

Industry Context

BridgeBio operates in the highly specialized and competitive genetic disease biopharmaceutical sector. Its decentralized model, focusing on multiple rare diseases, allows for tailored development and commercialization strategies. The company's progress with Attruby, a TTR stabilizer, positions it strongly against competitors in the ATTR-CM market. The development of a next-generation TTR amyloid depleter program indicates an ambition to address unmet needs beyond current stabilization therapies. The advancements in gene therapy and computational tools are creating a more actionable environment for genetic medicine, which BridgeBio aims to leverage. The company's pipeline addresses significant unmet needs in various rare conditions like LGMD2I/R9, ADH1, achondroplasia, Canavan disease, and EPP, where existing treatments are limited or non-existent.

Comparison to Industry Standards

• Attruby (acoramidis) for ATTR-CM is positioned as the "most potent stabilizer" with near-complete TTR stabilization in its label, differentiating it from other stabilizers like tafamidis (as per Prof. Jeffery Kelly's email). Its 42% reduction in composite cardiovascular outcomes and 50% reduction in cardiovascular-related hospitalizations at Month 30 are strong results compared to historical data for ATTR-CM treatments.
• The new TTR Amyloid Depleter Program is engineered with 4 novel properties (improved fibril:tetramer binding ratio, faster macrophage recruitment, pH sensitivity, half-life extension) to potentially differentiate from and overcome limitations of first-generation depleters from other companies.
• BBP-418 for LGMD2I/R9: The 2.6 point benefit on NSAD relative to placebo at 12 months is described as "highly clinically meaningful" and "unprecedented" across all pre-specified endpoints, suggesting a strong efficacy profile compared to the limited therapeutic landscape for this rare muscular dystrophy.
• Encaleret for ADH1 achieved a 76% responder rate in CALIBRATE, demonstrating superiority to conventional therapy (4% responder rate), setting a new potential standard of care for a condition with significant unmet needs. The company's efforts in establishing new ICD-10 codes and updating treatment guidelines are proactive steps in market development.
• Infigratinib for Achondroplasia demonstrated the "largest degree of efficacy (across multiple dimensions)" across any clinical trial for ACH, with a mean change from baseline in AHV of +2.51 cm/yr at M12 and mean absolute AHV >6 cm/yr at M12. This positions it strongly against existing or developing therapies for achondroplasia, such as vosoritide (BioMarin Pharmaceutical Inc.), which has shown an average increase in AHV of 1.57 cm/year. Its oral administration also offers a convenience advantage over injectable therapies.
• PORT-77 for EPP showed the "largest PPIX reduction seen to date" (up to ~75% at high dose) and rapid onset of action, indicating a potentially best-in-disease profile for Erythropoietic Protoporphyria, an area with limited standard of care.

Related Party Transactions

• BridgeBio Pharma, Inc. holds an 18.2% ownership stake in BridgeBio Oncology Therapeutics, an independent company.
• BridgeBio Pharma, Inc. holds a 27.5% ownership stake in GondolaBio, an independent company, with this interest subject to reduction as additional tranches of capital contributions are funded.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, robust pipeline progress, and multiple upcoming catalysts, potentially leading to increased share price and long-term value creation.
• Patients: Significant positive impact through the development and commercialization of transformative medicines for severe genetic diseases with high unmet needs, with an aim to double the number of patients served.
• Healthcare Professionals (HCPs): Attruby is becoming a first-choice therapy, and new therapies like BBP-418 and encaleret offer new treatment options, potentially improving patient outcomes and expanding diagnostic capabilities (e.g., ADH1 genetic testing).
• Employees: Continued growth and success of the company, reinforcing its mission and potentially leading to further opportunities.
• Regulatory Authorities: Ongoing interactions with the FDA for NDA submissions and clinical trial designs.

Next Steps

• Submit New Drug Application (NDA) for BBP-418 in LGMD2I/R9 in the first half of 2026.
• Submit New Drug Application (NDA) for encaleret in ADH1 in the first half of 2026.
• Initiate Phase 2/3 pediatric ADH1 trial for encaleret in the first half of 2026.
• Expect topline results for PROPEL 3 (infigratinib for achondroplasia) by the end of Q1 2026.
• Initiate RECLAIM-HP Phase 3 trial of encaleret in chronic hypoparathyroidism in Summer 2026.
• Expect Phase 2 data readout for infigratinib in hypochondroplasia in the second half of 2026.
• Anticipate FDA approval and product launch for BBP-418 in the second half of 2026.
• Anticipate FDA approval and product launch for encaleret in the first half of 2027.
• Potential Biologics License Application (BLA) filing for BBP-812 in Canavan disease in 2027.
• Advance new TTR amyloid depleter antibody program into the clinic between 2027-2028.
• Continue to accelerate Attruby commercialization.
• Potentially launch three additional medicines globally.
• Aim to double the number of patients served by the end of 2026.

Key Dates

Recommendation

The filing demonstrates exceptional progress across BridgeBio's diverse pipeline, with multiple late-stage programs yielding highly positive clinical data and receiving favorable regulatory feedback, including FDA recommendations for traditional full approval paths. The commercial success of Attruby is robust, and the company's strong cash position provides ample runway for upcoming launches and continued R&D. These factors collectively de-risk the investment thesis significantly and point to substantial future revenue growth and value creation, making it a compelling "strong buy" for a seasoned investor.

Keywords

Genetic diseases, Biopharmaceutical, ATTR-CM, Acoramidis, Attruby, LGMD2I/R9, BBP-418, Achondroplasia, Infigratinib, ADH1, Encaleret, Hypoparathyroidism, Canavan disease, BBP-812, Erythropoietic Protoporphyria, PORT-77, Clinical trials, FDA approval, NDA submission, Rare diseases, Pipeline, Commercialization, Financial results